Sequana Medical Announces That the Results of the alfapump® MOSAIC Study Have Been Published in Liver Transplantation
June 16, 2020 01:00 ET
|
Sequana Medical
North American feasibility study demonstrated the utility, safety and efficacy of the alfapump in the management of patients with recurrent and refractory ascites GHENT, Belgium, June 16, 2020 ...
Sequana Medical Announces the Appointment of Dr. Oliver Gödje as Chief Medical Officer
May 04, 2020 01:00 ET
|
Sequana Medical
GHENT, Belgium, May 04, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...
Sequana Medical Announces 2019 Full Year Results and 2020 Outlook
March 19, 2020 02:00 ET
|
Sequana Medical
Continued strong progress in U.S. NASH-related and global heart failure programs Successfully raised €19 million in Q1 2020 extending cash runway into H1 2021 Conference call with live webcast...
Sequana Medical Announces First-in-Human Data of Direct Sodium Removal (DSR) Therapy Published in Circulation
January 10, 2020 01:00 ET
|
Sequana Medical
Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for...
Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients
January 07, 2020 01:00 ET
|
Sequana Medical
The study aims to: Evaluate the safety of alfapump DSR in patients with heart failureAssess the feasibility of alfapump DSR to remove excess sodium and fluid from the bodyExplore the potential impact...
Sequana Medical Announces 2019 Half Year Results and Year-to-date Business Update
September 25, 2019 01:05 ET
|
Sequana Medical
Continued strong progress since IPO in February 2019: Commenced POSEIDON pivotal study to support approval of the alfapump® in the U.S. & CanadaAchieved clinical proof-of-concept of Direct Sodium...
Sequana Medical Announces First Patient Enrolled in North American alfapump® Pivotal Study (POSEIDON)
September 25, 2019 01:00 ET
|
Sequana Medical
Study aims to support the approval of the alfapump in U.S. and CanadaResults anticipated by mid-2021U.S. launch of the alfapump planned for H1 2022 GHENT, Belgium, Sept. 25, 2019 (GLOBE NEWSWIRE)...
Sequana Medical Appoints Leading Experts as Heart Failure Scientific Advisors
September 19, 2019 01:00 ET
|
Sequana Medical
Dr. Butler, Dr. Costanzo, Dr. Tang and Dr. Testani to advise on alfapump® DSR development GHENT, Belgium, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext...
Sequana Medical Announces Unconditional IDE Approval from U.S. FDA to Start alfapump® Pivotal Study (POSEIDON)
June 04, 2019 01:00 ET
|
Sequana Medical
alfapump pivotal study for treatment of recurrent or refractory ascites due to liver cirrhosisOptimised clinical trial design of up to 50 patients implanted with alfapump in study cohort and shorter...
Sequana Medical Announces Presentation of Positive DSR Clinical Proof-of-Concept Data Demonstrating Potential in Volume Overload Due to Heart Failure
May 27, 2019 02:30 ET
|
Sequana Medical
First-in-human single dose DSR study meets primary and secondary endpoints Direct Sodium Removal (DSR) was safe & well-tolerated Substantially higher sodium removal with DSR vs standard Peritoneal...